NSABP B-61 lidERA

B-61 lidERA

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC-9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen-Receptor Positive , HER2 Negative Early Breast Cancer

Patient Population:
Patients with Estrogen receptor positive, Her-2 negative early breast cancer

Target Accrual: 500 patients

Status: Not Recruiting

ClinicialTrials.gov Identifier: